COMMUNIQUÉS West-GlobeNewswire
-
Data on cenerimod – Idorsia's S1P1 receptor modulator – will be presented at the ACR / ARP Annual Meeting 2019
02/10/2019 - 17:35 -
EssilorLuxottica : Nombre total de droits de vote et d’actions composant le capital social au 30 septembre 2019
02/10/2019 - 18:00 -
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of September 30, 2019
02/10/2019 - 18:00 -
Allied Corp., a Medical Cannabis Company, Enters Into a Strategic Partnership Giving Access to The European Market
02/10/2019 - 18:23 -
‘Medicare for All’ Means Medicare for Nobody, States the Association of American Physicians and Surgeons (AAPS)
02/10/2019 - 18:51 -
SciCann Therapeutics receives notice of allowance for its enhanced CBD therapy US patent for NASH
02/10/2019 - 19:06 -
Vital, a Canon Group company, Recognized in Gartner’s Hype Cycle for Real-Time Health System Technologies, 2019 Report
02/10/2019 - 21:27 -
NEOVACS ANNOUNCES ITS 2019 HALF-YEAR RESULTS
02/10/2019 - 21:31 -
NÉOVACS ANNONCE SES RÉSULTATS SEMESTRIELS 2019
02/10/2019 - 21:31 -
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
02/10/2019 - 22:00 -
Monthly information regarding the total number of voting rights and total number of shares of the Company
02/10/2019 - 22:00 -
Lexicon Pharmaceuticals Announces Poster Presentations at the NANETS Annual Multidisciplinary NET Medical Symposium
02/10/2019 - 22:01 -
Aduro Biotech Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)
02/10/2019 - 22:05 -
EyePoint Pharmaceuticals Announces Permanent and Specific J-Code for YUTIQ® Now in Effect
02/10/2019 - 22:05 -
Novadip Biosciences Presents Clinical Case Study on Next Generation Tissue Regeneration Therapy for Critical Size Bone Reconstruction at EORS Conference
02/10/2019 - 07:00 -
Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
02/10/2019 - 07:15 -
Bone Therapeutics présentera des données précliniques sur les propriétés ostéogéniques d’ALLOB dans la régénération osseuse à l’occasion de la 27e réunion annuelle de l’EORS (European Orthopaedic Research Society)
02/10/2019 - 07:21 -
Bone Therapeutics to present preclinical data on the osteogenic properties of ALLOB in bone repair at 27th Annual Meeting of the European Orthopaedic Research Society
02/10/2019 - 07:21 -
Nicox : Les premiers résultats de l’étude de phase 2 Dolomites dans le glaucome montrent que le NCX 470 atteint le critère d’évaluation primaire et démontre une supériorité statistique vs. latanoprost
02/10/2019 - 07:30
Pages